comparemela.com

Latest Breaking News On - Without resistance post transplant - Page 1 : comparemela.com

Takeda Pharmaceutical Company Limited: Takeda Presents New Exploratory Analysis Showing Patients Treated With LIVTENCITY (Maribavir) Had Reductions in Hospitalization Rates and Length of Hospital Stay

Data Include Exploratory Analysis Showing LIVTENCITY Treated Patients With Post-Transplant Cytomegalovirus (CMV) Infections/Disease Had Reductions in Hospitalizations (34.8%; p=0.021) and Length

United statesSalt lake cityBarbara alexanderJun saitoClin virolErin marie bealsTakeda pharmaceuticals united states incEuropean congressInternational report on organ donationWorld health organizationDrug administrationInternational mediaExchange commissionTakeda pharmaceutical company limitedSpringer international publishingWorldwide network for blood

Takeda Announces Publication of Data from SOLSTICE, a Pivotal Phase 3 Trial for LIVTENCITY™ (Maribavir) in Post-Transplant Recipients With Cytomegalovirus (CMV) Infection (Refractory, With or Without Resistance)

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the data from the pivotal Phase 3 SOLSTICE clinical trial of LIVTENCITY™ (maribavir, TAK-620) in post-transplant refractory† CMV infections with or without resistance‡ (R/R) were published in the journal of Clinical Infectious Diseases (CID).

United statesClin virolTakeda pharmaceuticals united states incInternational report on organ donationTakeda pharmaceutical company limitedWorld health organizationTakeda pharmaceutical companyExchange commissionSpringer international publishingInfectious diseases society of americaThe global phaseNow published in clinical infectious diseasesShow for the primary endpointKey secondary endpointLower limit of quantificationSymptom control

vimarsana © 2020. All Rights Reserved.